CRISM Therapeutics Corporation
AMMCF
$6.77
$6.573,309.57%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -9.65M | -9.97M | -10.29M | -6.65M | -3.01M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.88M | 6.40M | 6.08M | 2.79M | -502.00K |
| Change in Net Operating Assets | -- | -- | -- | -- | -- |
| Cash from Operations | -2.77M | -3.57M | -4.21M | -3.86M | -3.52M |
| Capital Expenditure | -- | -- | 0.00 | -163.50K | -327.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00 | 17.50M | 35.00M | 17.50M | -- |
| Other Investing Activities | 34.93M | 16.38M | -1.58M | -1.08M | -581.50K |
| Cash from Investing | 34.93M | 34.21M | 33.82M | 16.65M | -511.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 0.00 | 0.00 | 172.50K | 345.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -31.45M | -30.37M | -29.29M | -14.65M | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -31.45M | -29.75M | -28.67M | -13.85M | 968.00K |
| Foreign Exchange rate Adjustments | 141.00K | 105.00K | 50.00K | 34.50K | 19.00K |
| Miscellaneous Cash Flow Adjustments | -668.00K | -334.00K | -- | -- | -- |
| Net Change in Cash | 187.00K | 647.00K | 966.00K | -1.05M | -3.06M |
